RSS | Login | Register

ALIMTA

Compare to Similar Drugs | Add to Clipboard | View Clipboard | Print | Email

Close [X]

Compare ALIMTA to:

ALIMTA (pemetrexed) 100mg/vial, 500mg/vial pwd for IV inj by Lilly

Generic Name for ALIMTA

Pemetrexed 100mg/vial, 500mg/vial; pwd for IV inj after reconstitution and dilution; preservative-free.

Legal Classification:

Pharmacological Class for ALIMTA

Antifolate.

Manufacturer of ALIMTA

Lilly, Eli and Company

Indications for ALIMTA

Locally advanced or metastatic nonsquamous non-small cell lung cancer: in combination with cisplatin as initial treatment, or as maintenance in patients whose disease has not progressed after 4 cycles of platinum-based 1^st-line chemotherapy; or as a single agent after prior chemotherapy. Malignant pleural mesothelioma (MPM): in combination with cisplatin in patients whose disease is either unresectable or who are otherwise not candidates for curative surgery.

Adult dose for ALIMTA

See literature. 500mg/m² by IV infusion over 10 minutes on Day 1 of each 21-day cycle. Adjust dose if toxicity (esp. myelosuppression) develops. Combination therapy: Give cisplatin beginning 30 minutes after pemetrexed infusion. Supplement with folic acid and vitamin B₁₂. Pretreat with corticosteroid.

Children's dosing for ALIMTA

Not recommended.

Precautions for ALIMTA

See literature. Renal impairment (CrCl <45mL/min): not recommended. Discontinue if Grade 3 or 4 neurotoxicity occurs, or if any Grade 3 or 4 toxicity occurs after two dose reductions. Do not start new cycle if ANC <1500cells/mm³ and platelet count <100,000cells/mm³. Hepatic impairment. Ensure adequate hydration. Monitor CBCs, platelets, renal and hepatic function. Clinically significant third space fluid: consider draining effusion first. Pregnancy (Cat.D); avoid, use effective contraception. Nursing mothers: not recommended.

Interactions for ALIMTA

May be potentiated by nephrotoxic agents, drugs eliminated by renal tubular secretion (eg, probenecid). Concomitant NSAIDs: use caution in patients with mild to moderate renal insufficiency (esp. ibuprofen).

Adverse Reactions for ALIMTA

Fatigue, GI upset, anorexia, stomatitis, pharyngitis, constipation, fever, infection with neutropenia, rash, desquamation, neutropenia, leukopenia, anemia, thrombocytopenia, elevated creatinine, chest pain, neuropathy; rare: renal failure.

How is ALIMTA supplied?

Single-use vial—1

Related Disease:

Malignant pleural mesothelioma

Neoplasms

Non-small cell lung cancer

Five-day dosing regimen for Dacogen approved for myelodysplastic syndromes (MDS)

March 12, 2010

The FDA has approved a five-day dosing regimen for Dacogen (decitabine for injection, from Eisai) to treat patients with myelodysplastic syndromes (MDS).

FDA cancer drug approval rate reviewed in JNCI

February 19, 2010

The FDA's Office of Oncology Drug Products approved 53 new indications for the use of oncology and hematology drugs and biologics from July 2005 to the end of 2007.

Phase 3 study of perifosine for metastatic colon cancer

February 03, 2010

Æterna Zentaris and Keryx Biopharmaceuticals announced agreement with the FDA regarding a Special Protocol Assessment on its Phase 3 trial for perifosine (KRX-0401) for the treatment of refractory metastatic colorectal cancer.

Exel/Exelint infusion set needles recalled

January 26, 2010

FDA notified healthcare professionals of a Class I recall of Exel/Exelint Huber needles, Exel/Exelint Huber Infusion Sets, and Exel/Exelint "Securetouch+" Safety Huber Infusion Sets due to 'coring,' the cutting or dislodging of silicone cores or slivers from the ports into which they are inserted).

Phase 2 study of ADXS11-001 for advanced cervical cancer

December 15, 2009

Advaxis announced that it will collaborate with the Gynecologic Oncology Group (GOG) in a Phase 2, multicenter clinical trial of ADXS11-011 for the treatment of advanced cervical cancer in women who have failed prior cytotoxic therapy.